We are live on ! Find out more
HEPA

Hepion Pharmaceuticals
HEPA

Delisted

HEPA was delisted on the 12th of May, 2025.

Back to rankings

3 hedge funds and large institutions have $4.44M invested in Hepion Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding

Funds holding: 1 → 3 (+2)

95% more capital invested

Capital invested by funds: $2.28M → $4.44M (+$2.16M)

Holders
3
Holders Change
+2
Holders Change %
+200%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AFM
Anson Funds Management
Texas
+$1.23M
2
TCIM
TIAA CREF Investment Management
New York
+$617K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$617K

Top Sellers

Rank Fund Capital Flow
1
SIM
Spark Investment Management
New York
-$139K
2
UBS Group
UBS Group
Switzerland
-$10K
3
JP Morgan Chase
JP Morgan Chase
New York
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
26
UBS Group
Switzerland
– -$10K – –
1
2

HEPA Hedge Fund Activity: Q1 2016 in Review

3 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q1 2016, worth a combined $4.44M — up 95% from $2.28M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new HEPA positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 0 trimmed.

The largest buyer was Anson Funds Management, opening a new position worth an estimated $1.23M. The largest seller was Spark Investment Management, cutting an estimated $139K.

  • 3 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q1 2016, up from 1 in Q4 2015.
  • Funds reported $4.44M of Hepion Pharmaceuticals stock for Q1 2016, up 95% quarter-over-quarter.
  • 2 funds opened new Hepion Pharmaceuticals positions in Q1 2016 and 0 closed out, a net change of +2 holders.
  • The largest Hepion Pharmaceuticals buyer in Q1 2016 was Anson Funds Management, an estimated $1.23M added.
  • The largest Hepion Pharmaceuticals seller in Q1 2016 was Spark Investment Management, an estimated $139K sold.

Based on aggregated 13F filings for Q1 2016.